Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More impact case studies

Ensuring reliability in large clinical trials for dementia

When investigating the brain, scientists work with datasets containing vast amounts of detail. This includes the brain scans that they’ll be working with. Variations between images could indicate a particular character of the Alzheimer’s disease development. They could indicate the role of a particular chemical in the brain, or the role of a particular area in the brain.

Study into early Alzheimer's disease treatments

The New Therapeutics into Alzheimer's Disease (NTAD) study is looking to detect markers of the disease before symptoms show. These markers for the disease will be used to test whether experimental treatments can delay, or even prevent, the progression of the disease.

Tau-PET imaging

Researchers will carry out additional PET scanning of 100 people who have already had PET scans as part of their involvement in two existing health study cohorts – EPAD and PREVENT. The extra information they collect on the 'tau' protein, when combined with existing data from these participants, will create a very rich dataset for modelling the early stages of Alzheimer's disease and subsequent dementia.